The results obtained by Zhang et al., who observed that high levels of ADARB2 expression are associated with a better prognosis in patients with low-grade glioma, and their multivariate analysis suggests that it is an independent prognostic factor [59]. Here, ADARB2 is linked to central nervous system cancer.